DAratumumab iN combination with BorTEzomib and Dexamethasone in subjects with relapsed or relapsed and refractory Multiple Myeloma and severe renal impairment including subjects undergoing hemodialysis. A phase 2, open-label, multicenter trial
Latest Information Update: 09 Feb 2023
At a glance
- Drugs Bortezomib (Primary) ; Daratumumab (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms GMMG-DANTE
- 17 Jun 2022 Primary analysis presented at the 27th Congress of the European Haematology Association
- 27 May 2022 Status changed from active, no longer recruiting to completed.
- 05 Oct 2021 This trial has been discontinued in Greece, according to European Clinical Trials Database record.